Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Conduit Pharmaceuticals Inc. (CDTTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/03/2025: CDTTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.29% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/03/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -168.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 552357 |
Shares Outstanding - | Shares Floating 552357 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Conduit Pharmaceuticals Inc.
Company Overview
History and Background
Conduit Pharmaceuticals Inc. (CDT) was founded in 2020 as a special purpose acquisition company (SPAC) and subsequently acquired and merged with a late-stage biopharmaceutical company. The aim is to develop new treatments for unmet medical needs.
Core Business Areas
- Human therapeutics: Conduit is focussed on late-stage small molecule therapeutics including inflammatory disease, infectious disease, and other human ailments.
Leadership and Structure
Details regarding Conduit Pharmaceuticals' leadership team and organizational structure can be found on the company's investor relations webpage. Focus is on bringing late stage assets to market.
Top Products and Market Share
Key Offerings
- AZD1656 (exenatide extended release): A once-weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) for the treatment of type 2 diabetes. Competitors include Novo Nordisk (NVO) and Eli Lilly (LLY) with their respective GLP-1 receptor agonists. Market share data is pending market entrance.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, long regulatory approval processes, and intense competition. Innovation is key, and companies must adapt to evolving healthcare needs and regulatory landscapes.
Positioning
Conduit Pharmaceuticals is positioned as a late-stage development company focused on bringing assets to market. Its competitive advantage hinges on efficient development and commercialization.
Total Addressable Market (TAM)
The TAM for diabetes and other inflammatory diseases is estimated to be several billion dollars. CDT is positioned to address a portion of this TAM with its late-stage asset.
Upturn SWOT Analysis
Strengths
- Late-stage product pipeline
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited commercial infrastructure
- Dependence on successful clinical trials
- Limited revenue
Opportunities
- Expanding into new therapeutic areas
- Partnerships and collaborations
- Market entry for lead products
Threats
- Regulatory hurdles
- Competition from established players
- Clinical trial failures
- Patent Expiry
Competitors and Market Share
Key Competitors
- NVO
- LLY
- SNY
- MRK
Competitive Landscape
Conduit Pharmaceuticals faces significant competition from established pharmaceutical companies with greater resources and commercial infrastructure. CDT's advantages lie in its late-stage assets and focused development strategy.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is not applicable given the company's recent formation and developmental stage.
Future Projections: Future growth is dependent on successful clinical trials, regulatory approvals, and market acceptance of its products. Analyst projections should be referred to.
Recent Initiatives: Recent strategic initiatives involve clinical trial progression and regulatory submissions.
Summary
Conduit Pharmaceuticals is a developmental-stage company focusing on late-stage assets in areas of unmet medical need. It possesses a high-risk, high-reward profile and lacks significant commercial operations. Its success hinges on successful clinical trials, regulatory approvals, and partnerships and market entry. Key watch-outs are the competition from large pharmaceutical firms and potential regulatory hurdles and reliance on capital markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Financial news sources
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data is estimated and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Conduit Pharmaceuticals Inc.
Exchange NASDAQ | Headquaters Naples, FL, United States | ||
IPO Launch date 2023-09-25 | Founder, CEO & Director Dr. Andrew Regan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.conduitpharma.com |
Full time employees 6 | Website https://www.conduitpharma.com | ||
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.